According to the report, the global pharmaceutical contract manufacturing market is likely to grow from USD 215.3 Billion in 2025 to USD 443.7 Billion in 2035 at a highest CAGR of 7.5% during the time period. The pharmaceutical contract manufacturing market is booming due to an increasing number of pharmaceutical companies and biotechnology outsourcing their drug development and manufacturing processes for a variety of reasons, including the need to reduce capital costs, shorten time to market, and focus on their core research capabilities.
Thus, pharmaceutical manufacturers are increasingly turning to contract manufacturing organizations (CMOs) to supply active pharmaceutical ingredients (APIs), assist with formulation development, and produce finished dosage forms as they look to improve their operational efficiencies, scalability, and regulatory compliance.
Additionally, the increasing complexity of drug development pipelines such as biotech products (biologics), very-high-potency APIs, and sterile injectable forms are contributing to a growing demand for specialized manufacturing capabilities. Moreover, there is a rising need for generic products, biosimilars, and personalized medicine in developing countries, and CMOs expected to benefit from this.
Recent advancements in continuous manufacturing, single-use equipment, and quality-by-design methods have also given CMOs greater flexibility in production operations while meeting the stringent regulatory requirements imposed by government agencies. Other factors boosting the growth of the pharmaceutical contract manufacturing market include an increase in pharmaceutical spending, increased access to the healthcare system, and limitations on the capacity of internal manufacturers.
Key Driver, Restraint, and Growth Opportunity Shaping the Global Pharmaceutical Contract Manufacturing Market
One of the major drivers of the global pharmaceutical contract manufacturing industry is the demand for additional capacity without significant capital investment. As companies continue to develop their capabilities to meet the demand for chronic disease therapies and speed up their ability to commercialize new products, they are increasingly outsourcing their manufacturing needs. Additionally, as larger amounts of smaller batches of specialty drugs are manufactured, many companies expected to look to enhance their use of contract manufacturing organizations (CMOs) as well.
However, CMOs continue to face challenges in meeting varying regulatory requirements and ensuring consistency among all CMOs around the world. Regulatory requirements from agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) are well defined, yet fulfilling them is an increasing challenge due to numerous geographic areas; however, the variability in the regulatory requirements and the resultant variability in inspection outcomes may result in greater complexity to operate and longer delays for obtaining approval of a product.
Another area of opportunity is in the area of biologics, which continue to be a high growth area. Companies with specialized capabilities, such as aseptic processing and high-potency manufacturing, are going to be at the forefront of supporting innovation and capturing other long-term growth opportunities that become available through the continued increase in the demand for biologics, biosimilars, and advanced drug delivery systems
Expansion of Global Pharmaceutical Contract Manufacturing Market
Outsourcing Demand, Advanced Manufacturing Technologies, and Capacity Expansion Driving Pharmaceutical Contract Manufacturing Market Growth
The driving forces behind the growth of contract manufacturing in the pharmaceutical/biotechnology industries include outsourcing demand, new technology in manufacturing processes, and the continued expansion of production capabilities. As a way to decrease the amount of money spent on capital expenditures and to shorten the time it takes to bring manufactured products to market, pharmaceutical and biotechnology companies are increasingly turning to CMOs for both drug development and commercial production, utilizing their specialized expertise to produce complex biologics and high-potency APIs.
Additionally, through ongoing investments in automation, digitization, single-use systems, and advanced processes, CMOs are improving the efficiency and quality of their contract manufacturing services. As the result of predictions by various industry sources, CMOs are rapidly growing their capabilities and service offerings worldwide, with many CMOs investing heavily in niche biologics production capabilities as well as state-of-the-art manufacturing technologies to meet the rising demand for contract manufacturing services.
Furthermore, some of the latest strategic contract manufacturing capacity expansion examples include WuXi Biologics’ plan to deploy fully automated continuous drug substance manufacturing operations in 2025 and Regeneron’s execution of a more than USD 3 billion manufacturing agreement with Fujifilm Diosynth to nearly double its manufacturing capacity in the United States, which illustrates the strong demand for contract manufacturing services as the pharmaceutical/biotechnology landscape changes.
Regional Analysis of Global Pharmaceutical Contract Manufacturing Market
Prominent players operating in global pharmaceutical contract manufacturing market includes key players such as AbbVie Contract Manufacturing, Adare Pharmaceuticals, Aenova Group, Alcami Corporation, Boehringer Ingelheim BioXcellence, Catalent Pharmaceuticals, Consort Medical (Recipharm), Dishman Carbogen Amcis, Famar Health Care Services, Fareva, Lonza Group, Metrics Contract Services, Millmount Healthcare, Nephron Pharmaceuticals, Patheon (Part of Thermo Fisher), Piramal Pharma Solutions, Recipharm, Samsung Biologics, Siegfried Holding, Thermo Fisher Scientific (Patheon), Vetter Pharma International, along with several other key players.
The global pharmaceutical contract manufacturing market has been segmented as follows:
Global Pharmaceutical Contract Manufacturing Market Analysis, by Service Type
Global Pharmaceutical Contract Manufacturing Market Analysis, by Drug Development Phase
Global Pharmaceutical Contract Manufacturing Market Analysis, by Therapeutic Area
Global Pharmaceutical Contract Manufacturing Market Analysis, by Drug Classification
Global Pharmaceutical Contract Manufacturing Market Analysis, by Type of Contract
Global Pharmaceutical Contract Manufacturing Market Analysis, By Packaging Type
Global Pharmaceutical Contract Manufacturing Market Analysis, By End-users
Global Pharmaceutical Contract Manufacturing Market Analysis, By Region
About Us
MarketGenics is a global market research and management consulting company empowering decision makers from startups, Fortune 500 companies, non-profit organizations, universities and government institutions. Our main goal is to assist and partner organizations to make lasting strategic improvements and realize growth targets. Our industry research reports are designed to provide granular quantitative information, combined with key industry insights, aimed at assisting sustainable organizational development.
We serve clients on every aspect of strategy, including product development, application modeling, exploring new markets and tapping into niche growth opportunities.
Contact US
USA Address:
800 N King Street Suite 304 #4208 Wilmington, DE 19801 United States.
+1(302)303-2617
India Address:
3rd floor, Indeco Equinox, Baner Road, Baner, Pune, Maharashtra 411045 India.
Table of Contents
Note* - This is just tentative list of players. While providing the report, we will cover more number of players based on their revenue and share for each geography
We will customise the research for you, in case the report listed above does not meet your requirements.
Get 10% Free Customisation